2 - Pharmacology Of Peripheral Neurotransmission Flashcards
Tetanus toxin
Retrogradely transported to motor cell body
Transfers to inhibitory inter neutron, blocking it
Motor neuron more excitable
Targets SNARE synaptobrevin
Botulinum toxins
Preferentially effects cholinergic neurons
C terminus of heavy chain binds ganglioside receptor
N terminus translocation light chain into the cell through a channel
Light chain has peptidase activity, and once inside, cleaves the snare
Blocks ACh release
Botulinum toxin C1
Target
Syntaxin and SNAP25
Botulinum toxins A&E
Target
SNAP25
Botulinum toxins B,D,F,G
Target
Synaptobrevin
Hemicholinium
Blocks transporter that takes up choline into nerve cell
Vesamicol
Blocks transporter that carries ACh into storage vesicles
Non-Competitive and reversible inhibition
B-bungarotoxin
Blocks ACh release
Acts through phospholipase A2
a-latrotoxin
Binds neurexins
Cause massive release if ACh
Trimetaphan
Blocks ganglionic nicotinic receptors
Competitive antagonist
a-bungarotoxin
Irreversible antagonist at nmj
Doesn’t affect ganglionic receptors
Nicotine
Stimulates post synaptic cell
Long-lasting
Phase I block - VGNa channels inactivated
Phase II block - nicotinic receptors become desensitised
In phase II can be directly stimulated by electrical means
Hexamethonium
Use dependent blockade of ganglionic transmission
Double positive charge - had to be administered frequently by injection
Causes loss of sympathetic and parasympathetic control
D-tubocurarine
Nicotinic receptor antagonist
Non selective between ganglion and nmj
Quaternary ammonium compounds so not orally active
Atracurium
Competitive antagonist at the nicotinic receptor of the nmj
Quaternary ammonium compound
Not orally active
Block end plate potential in response to nerve stimulation
Antagonise affects directly applied by ACh etc
Tetanic fade (tetanus is not maintained) due to block of nicotinic receptors on nerve endings auto receptors , positive feedback to maintain transmitter release
Ester - spontaneous hydrolysis and plasma esterases
Pancuronium
Competitive antagonist at the nicotinic receptor of the nmj
Quaternary ammonium compound
Not orally active
Block end plate potential in response to nerve stimulation
Antagonise affects directly applied by ACh etc
Tetanic fade (tetanus is not maintained) due to block of nicotinic receptors on nerve endings auto receptors , positive feedback to maintain transmitter release
Long action, not hydrolysed
Decemethonium
Block nicotinic receptor at nmj by causing prolonged depolarisation
Depolarisation of phase I- anticholinesterases deepen the blockade
Effects can be opposed by non-depolarising blockers
Phase II - repolarisation, anticholinesterases reverse the blockade
Suxamethonium
Block nicotinic receptor at nmj by causing prolonged depolarisation
Depolarisation of phase I- anticholinesterases deepen the blockade
Effects can be opposed by non-depolarising blockers
Phase II - repolarisation, anticholinesterases reverse the blockade
Only depolarising blocker in clinical use
Short duration - ester broken down by plasma BuCHE
Carbachol
Non selective agonist at muscarinic acetyl choline receptors
Not selective between nicotinic and muscarinic receptors
Muscarine
Muscarinic receptor (agonist)
Methacholine
Agonist for muscarinic receptors
2 isomers
Neither hydrolysed by BuCHE
(+) is a substrate for AChE. More potent than at muscarinic receptors (-)
Acetylcholine
Non selective agonist at muscarinic acetyl choline receptors
Bethanechol
Non selective agonist at muscarinic acetyl choline receptors
Poorly absorbed in GI tract
Systemic use in bladder dysfunction
Pilocarpine
Non selective agonist at muscarinic acetyl choline receptors
Poorly absorbed from GI tract
Treatment of glaucoma, contracts ciliary muscle
Atropine
Non selective antagonist of muscarinic acetylcholine receptor Dilate pupils (mydriasis) Long duration
Benzilylcholine mustard
Non selective antagonist of muscarinic acetylcholine receptor
Pirenzepine
Antagonist of m1 muscarinic acetylcholine receptor
Anti secretory agent, gastro duodenal ulcers
Darifenacin
Antagonist m3 muscarinic acetylcholine receptor
Mediate bladder constriction
Edrophonium
Short acting, reversible ionic interaction with AChE
Used for diagnosis of myasthenia gravis
Neostigmine
Medium acting reversible weak covalent bond with AChE
Orally treats myasthenia gravis
Bind esteratic site and carbomylate enzyme
Intravenously to reverse neuromuscular blockade